Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 7.7277
- Book/Share 3.3466
- PB 4.1482
- Debt/Equity 0.0
- CurrentRatio 0.8682
- ROIC 0.1098
- MktCap 58366596169.728
- FreeCF/Share 0.8929
- PFCF 16.0216
- PE 18.6254
- Debt/Assets 0.0
- DivYield 0.0415
- ROE 0.2244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132893&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132868&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK) Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132755&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
Read More
GSK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of GSK plc to Contact the Firm Today!
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
Read More
Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact The Gross Law Firm
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132592&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors who Lost Money on GSK plc (GSK) Should Contact Levi & Korsinsky about Pending Class Action - GSK
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132559&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132550&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132487&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of GSK plc (GSK) Shareholders
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).
Read More
GSK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of GSK plc to Contact the Firm Today!
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
Read More
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132273&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132268&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. So what: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=132252&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, 2022. GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline.
Read More
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers.
Read More
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 25, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK).
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against GSK plc
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE:GSK) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2025.
Read More
Lost Money on GSK plc(GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022.
Read More
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131966&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit – GSK
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131919&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131886&wire=1 or contact Joseph E. Levi, Esq.
Read More
A Securities Fraud Lawsuit Has Been Filed Against GSK plc And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE:GSK) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2025.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Ms. Emma Natasha Walmsley
- Employees 68629